Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Myhibbin (mycophenolate mofetil) Oral Suspension for Prophylaxis of Organ Rejection
WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products...
US FDA Approves High-Concentration, Citrate-Free Formulation of Cyltezo (adalimumab-adbm) injection
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of...
Dogs Brought to U.S. Must Be Microchipped, Older Than 6 Months: CDC
Dogs brought into the United States from abroad must be compliant with new rules to help fight rabies in this country, according to updated guidance from...
MRE-Liver Stiffness Measure Better for Varices in NAFLD Cirrhosis
For patients with obesity and nonalcoholic fatty liver disease (NAFLD) compensated cirrhosis (CC), liver stiffness measurement (LSM) by magnetic resonance...
Maltreatment as a Child Ups Odds of Substance Use Admissions by Age 40 Years
People with a history of child maltreatment (CM) appear to have significantly higher odds of inpatient admissions for alcohol use disorders (AUDs) and...
More Than 321,000 U.S. Kids Lost a Parent to Drug ODs in a Decade
More than 320,000 U.S. children lost a parent to drug overdose during the past decade, according to a new study reported May 8 in JAMA Psychiatry. What’s...
Systemic Antibiotics in First Year of Life Tied to Higher Atopic Dermatitis Risk
Systemic antibiotic exposure in the first year of life is associated with higher atopic dermatitis (AD) risk in a dose-response fashion, according to a...
Trifarotene Plus Skin Care Beneficial for Acne Vulgaris
Trifarotene plus skin care is beneficial for patients with moderate acne vulgaris (AV) and acne-induced hyperpigmentation (AIH), according to a study published...
About 90% of U.S. Adults Are On the Way to Heart Disease
Nine of 10 American adults are in the early, middle or late stages of a syndrome that leads to heart disease, a new report finds, and almost 10% have the...
There's a New Set of COVID Variants Called FLiRT: What You Need to Know
The virus behind COVID has mutated again, this time producing variants nicknamed FLiRT, the U.S. Centers for Disease Control and Prevention (CDC) has reported. The...
Positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
STOCKHOLM, May 6, 2024. Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its...
Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published
SAN ANTONIO, May 3, 2024. Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment...
An Orangutan Healed Himself With Medicinal Plant
Primates are capable of tending to wounds using medicinal plants, a new case report says. A male Sumatran orangutan treated a facial wound with a climbing...
Recently Added
Recently added consumer and prescribing information: Myhibbin, Rezenopy, Libervant, Beqvez, Xolremdi, Pivya, Xromi, Risvan, Voydeya, Winrevair
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Myhibbin Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection.
- Libervant Libervant (diazepam) is a buccal film formulation of the benzodiazepine diazepam that may be given to treat children aged 2 to 5 years with...
- Xolremdi Xolremdi (mavorixafor) is a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...